Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

BACKGROUND: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC a...

Descripción completa

Detalles Bibliográficos
Autores principales: Senan, S., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., Hui, R., Faivre-Finn, C., Paz-Ares, L., Wu, Y.L., Mann, H., Dennis, P.A., Antonia, S.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058904/
https://www.ncbi.nlm.nih.gov/pubmed/35247871
http://dx.doi.org/10.1016/j.esmoop.2022.100410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058904/
https://www.ncbi.nlm.nih.gov/pubmed/35247871
http://dx.doi.org/10.1016/j.esmoop.2022.100410

Ejemplares similares